Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Patient-Centered Outcomes Research Institute | OTHER |
| Iowa State University | OTHER |
Not provided
Not provided
Not provided
Not provided
This study will perform a retrospective analysis to evaluate the effectiveness of a multicomponent educational intervention to improve medication use and management of behavioral and psychological symptoms of dementia, relative to a statewide intervention that has been ongoing. Medication use and symptom severity outcomes will be compared among intervention counties and demographically similar non-intervention counties.
This study will perform a retrospective analysis to evaluate the effectiveness of a multicomponent educational intervention to improve medication use and management of behavioral and psychological symptoms of dementia, relative to a statewide intervention that has been ongoing. Medication use and symptom severity outcomes will be compared among 29 intervention counties and 10 demographically similar non-intervention counties. The long-term effectiveness of the statewide intervention will also be evaluated. Medicare and Minimum Data set data from 2011 to 2014 will be used to evaluate prescribing and other outcomes in 1) outpatients with dementia, and 2) nursing home residents, based on exposure to interventions among healthcare and nursing home providers. Measurable goals included increasing the appropriateness of antipsychotic prescribing and reducing anticholinergic use. Effect modification will be evaluated by level of participation in the intervention and other prescriber and nursing home facility characteristics.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Outpatients with dementia | Medication use will be evaluated among outpatients with dementia in intervention and control counties, as well as statewide to evaluate the long-term effectiveness of the statewide intervention. |
| |
| Nursing home residents | Medication use and behavioral outcomes will be evaluated among nursing home residents in intervention and control counties, as well as statewide to evaluate the long-term effectiveness of the statewide intervention. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Educational activities to improve dementia care | Behavioral | The multicomponent intervention included active dissemination of educational resources and optional participation in specialist consultation sessions for up to 6 months. The standard intervention included education through a website or conferences, including clinical tools to support implementation of best practices. |
| Measure | Description | Time Frame |
|---|---|---|
| Antipsychotic use | Antipsychotic use | Up to 4 years |
| Anticholinergic Use | Anticholinergic use | Up to 4 years |
| Measure | Description | Time Frame |
|---|---|---|
| Olanzapine use in patients with metabolic disorders | Proportion of antipsychotic users with diabetes mellitus, hyperlipidemia, or hypertension (based on diagnosis indicators from claims) who receive olanzapine, the least appropriate antipsychotic when these conditions are present due to its metabolic effects. | Up to 4 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All Iowa Medicare beneficiaries who are nursing home residents or diagnosed with dementia and meet other eligibility criteria, for each year from 2011 to 2014.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ryan Carnahan, PharmD, MS | University of Iowa | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The University of Iowa College of Public Health | Iowa City | Iowa | 52246 | United States |
Other than exposure data which is identifiable, the evaluation is based on CMS data which cannot be shared without a data reuse agreement.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003704 | Dementia |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D019965 | Neurocognitive Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Excessive antipsychotic dose |
Antipsychotic doses as defined as excessive by CMS standards for nursing home residents with dementia |
| Up to 4 years |
| Benzodiazepine use | Benzodiazepine use. Time frame differs because Medicare Part D did not pay for these drugs until 2013. | Up to 2 years |
| Quetiapine or clozapine use only among antipsychotic users with Parkinson's disease or Lewy body dementia | Quetiapine or clozapine use only among antipsychotic users with Parkinson's disease or Lewy body dementia. These are the most appropriate antipsychotics in these conditions. | Up to 4 years |
| Antipsychotic use in people with dementia | Antipsychotic use in people with dementia. This is a subgroup analysis of the nursing home population. | Up to 4 years |
| Antipsychotic use in nursing home residents with a potentially appropriate indication | Proportion of antipsychotic users with evidence of a potentially appropriate indication, stratified by indication, as follows: verbal or physical aggression, delusions, hallucinations, delirium | Up to 4 years |
| Antipsychotic use in nursing home residents without a potentially appropriate indication, and proportion with evidence of an inappropriate indication | Antipsychotic use in those without a potentially appropriate indication, and proportion of those users with evidence of an inappropriate indication | Up to 4 years |
| Antipsychotic use in nursing home residents with a recent history of falls | Antipsychotic use in those with a recent history of falls (fall indicator on any MDS assessment in the prior 6 months) | Up to 4 years |
| Antipsychotic use in nursing home residents with an unsteady gait | Antipsychotic use in nursing home residents with an unsteady gait, as evaluated by MDS records | Up to 4 years |
| Hypnotic use | Hypnotic use as measured by MDS indicator | Up to 4 years |
| Changes in behavioral and psychological symptom presence | Changes in behavioral symptom frequency (each of verbal aggression, physical aggression, delirium, hallucinations, delusions) | Up to 4 years |
| D001523 | Mental Disorders |